SABSW | SAB Biotherapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0502 - 0.0875
52 Week Range	0.0502 - 0.0875
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	23,172
Average Volume	N/A
Shares Outstanding	586,330,098
Market Cap	41,043,127
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-10-25

Valuation
Profitability
Growth
Health
P/E Ratio	0.24
Forward P/E Ratio	N/A
EPS	0.29
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	USA
Website	SABSW

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

SABSW's peers: CING, EDSA, NRXP, SABS, JSPRW, NRXPW, ROIVW, SRZNW, SNTI, REVBW, IMNN

*Chart delayed

Analyzing fundamentals for SABSW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is very weak. For more detailed analysis please see SABSW Fundamentals page.

Watching at SABSW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SABSW Technicals page.